ROCK as a Therapeutic Target of Diabetic Retinopathy by Arita, Ryoichi et al.
Hindawi Publishing Corporation
Journal of Ophthalmology
Volume 2010, Article ID 175163, 9 pages
doi:10.1155/2010/175163
Review Article
ROCK as a TherapeuticTarget of Diabetic Retinopathy
Ryoichi Arita,YasuakiHata,and TatsuroIshibashi
Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku,
Fukuoka 812-8582, Japan
Correspondence should be addressed to Yasuaki Hata, hatachan@med.kyushu-u.ac.jp
Received 2 December 2009; Accepted 9 April 2010
Academic Editor: Kavita Hegde
Copyright © 2010 Ryoichi Arita et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The increasing global prevalence of diabetes is a critical problem for public health. In particular, diabetic retinopathy, a
prevalent ocular complication of diabetes mellitus, causes severe vision loss in working population. A better understanding of
the pathogenesis and the development of new pharmacologic treatments are needed. This paper describes the relevance between
Rho/ROCK pathway and the pathogenesis of diabetic retinopathy from its early to late stages. Moreover, the therapeutic potential
of ROCK inhibitor in the total management of diabetic retinopathy is discussed.
1.Introduction
The growing prevalence of diabetic retinopathy (DR), the
common ocular complication of diabetes mellitus, is a
critical problem for global public health [1, 2]. Early
nonproliferative stages of DR are characterized by blot
hemorrhages and vascular abnormality such as retinal
vascular microaneurysms or hyperpermeability which could
cause diabetic macular edema (DME). Proliferative diabetic
retinopathy (PDR), later stage of the diseased state, causes
neovascularization, vitreous hemorrhages, preretinal ﬁbro-
vascular proliferation, and tractional retinal detachment.
While visual acuity is not always aﬀected in early stages,
progression of the disease leads to severe vision loss.
Panretinal photocoagulation (PRP) and vitreoretinal
surgery remain the primary therapeutic strategies for pro-
gressed DR. However, PRP is destructive to the retina and
accompanied by adverse eﬀects such as decreased visual
acuity, increased risk of macular edema, and pain [3,
4]. Moreover, recent advances in vitreous surgery cannot
always achieve a satisfying visual acuity [5]. Now it is at a
point where new alternative and adjunctive agents from the
earlier stages are urgently required because of overwhelming
patient’s physical and economic burdens of these treatments.
The various clinical ﬁndings in earlier DR stages
are related to endothelial damage secondary to increased
leukocyte adhesion mediated through adhesion molecules,
intercellular adhesion molecule-1 (ICAM-1), and leukocyte
β2-integrins (CD18/CD11a and CD18/CD11b) [6–8]. In
addition, the critical mechanism of this leukocyte-induced
endothelial damage is the interaction of endothelial Fas with
Fas ligand, expressed on adherent leukocytes in diabetic rats
[9] and DR patients [10].
Recent accumulating evidences indicate that vascular
endothelial growth factor (VEGF) plays a critical role in
pathogenesis of both DME and neovascularization in PDR
[11, 12]. Clinical studies with anti-VEGF antibodies are
potentially useful strategy and improve outcome for treating
DR [13]. However, the adaptation is only for progressed
states and there is a possibility of systemic adverse compli-
cations such as hypertension, cerebrovascular accidents, and
myocardial infarcts by anti-VEGF therapy [14].
Meanwhile, neovascularization and proliferative vitre-
oretinopathy (PVR) are hallmark of the later DR stages.
VEGF-induced endothelial migration and proliferation is
essential process for angiogenesis. ERK1/2 signaling pro-
motes the proliferative activities of endothelial cells in angio-
genic processes [15, 16]. Moreover, endothelial migration is
mediated by Rho-kinase (ROCK) pathway which activates
remodeling of endothelial F-actin cytoskeleton [17].
Our recent ﬁndings indicated that hyalocytes, a known
resident macrophage in the cortical vitreous under physi-
ological conditions, appeared to be involved in the patho-







































































































































Figure 1: Rho/ROCK activation in retinal vessels. In immunohistochemical analysis, RhoA (a), ROCK1 (b) and ROCK2 (c) were detected in
retinal vessels. Yellow (white arrowhead) indicates double-stained vasculature (magniﬁcation: ×400). (d and e) The levels of Rho-GTP were
signiﬁcantly higher in streptozotocin induced-diabetic rat bretinas, compared with those in nondiabetic control, detected by Rho pull-down
assay. Average signal intensities are quantiﬁed and expressed as percentage of the ratio of control (∗∗P<. 01, n = 5 each). Prevention of
leukocyte-induced retinal endothelial damage by fasudil. (f–i) In vivo visualization of adhering leukocytes (green, concanavalin A lectin) and
injured endothelial cells (red, propidium iodide (PI)) and endothelial nuclei (blue, DAPI) in rat retinas. PI positive cells (white arrowhead)
widely coincided with adherent leukocytes (white arrow). The number of PI positive cells per retina was signiﬁcantly higher in the diabetic
animals, compared with the nondiabetic controls. Fasudil caused a signiﬁcant reduction in the number of PI positive cells in the retinas of
the diabetic animals, compared with the vehicle-treated controls (∗∗P<. 01, N.S., not signiﬁcant, n = 5 each).
proliferative membranes in PDR [18–20]. The expression
of α-smooth muscle actin (α-SMA) and phosphorylation of
myosin light chain (MLC) in hyalocytes, which is associated
withstress-ﬁberformationandcontractilerings,arefacilitat-
ing cell contraction [21, 22]. We demonstrated that vitreous
from patients with PDR signiﬁcantly promoted expression
of α-SMA and phosphorylation of MLC, and enhanced
contraction of hyalocyte-containing collagen gels, compared
with vitreous from patients with nondiabetic controls [23].
In this paper, we ﬁrst place the Rho/ROCK pathway plays
a critical role in diabetic retinal microvasculopathy, neo-
vascularization, and tractional retinal detachment associated
with a cicatricial contraction of proliferative membranes. We
























































































Figure 2: Continued.4 Journal of Ophthalmology
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Figure 2: Impact of fasudil on PDR vitreous-induced collagen gel contraction and MLC phosphorylation. After pretreatment with
or without anti-TGF-β mAb or fasudil, hyalocytes were stimulated with vitreous with PDR. (a) In hyalocyte-containing collagen gels,
fasudil almost completely suppressed the contraction of collagen gels treated with PDR vitreous. The diameter of the gels was measured
and statistically analyzed (∗P<. 05; ∗∗P<. 01; NS, not signiﬁcant, n = 3 each). (b) Western blot analysis was performed to
detect phosphorylated MLC (pMLC). Fasudil abolished MLC phosphorylation, induced by PDR vitreous. Lane-loading diﬀerences were
normalized by MLC. Signal intensities were quantiﬁed and expressed as percentages of the pMLC/MLC ratio compared with control
(∗P<. 05; ∗∗P<. 01, n = 3 each). Experimental PVR in rabbit eyes. (c) Therapeutic potential of fasudil in reducing the progression
of experimental PVR. PVR was classiﬁed into six stages (0–5). Rhombus, vehicle (n = 5); purple square, fasudil 10μM( n = 5); trigone,
fasudil 30μMf r o ms t a g e2( n = 6); blue square, fasudil 30μM( n = 5) (∗P<. 05, ∗∗P<. 01, not signiﬁcant versus vehicle). (d) Tractional
retinal detachment because of formation and cicatricial contraction of preretinal proliferative membrane was observed by stereomicroscopy
in vehicle-treated eyes (stage 5 PVR). (g) In contrast, intravitreal membranes adhered to the retina without causing retinal detachment
(arrowhead) in 30μM fasudil-treated eyes with stage 2 PVR. Micrographs depict α-SMA expression (brown) in preretinal proliferative
membrane with stage 5 PVR (e) and stage 2 PVR (h) by immunohistochemical analysis. (Scale bar, 200μm). (f and i) Magniﬁed images of
(e) and (h), respectively, (Scale bar, 10μm).
as a new strategy in the total management of DR from its
early to late stages.
2. Involvement of Rho/ROCK Pathway in
the Pathogenesis ofDiabeticRetinopathy
Recent studies have revealed that small GTP-binding protein
Rho and its target protein ROCK are implicated in the
important physiological roles such as cell adhesion and
migration mediated through MLC phosphorylation [19, 24].
Rho activity is also increased in bovine aortic endothelial
cells treated with high glucose [25], and involved in the
pathogenesis of renal and aortic complications during
diabetic states [26, 27]. Furthermore, we revealed that
Rho/ROCK pathway is activated in retinal microvessels
during diabetes (Figures 1(a)–1(e)).
Rho/ROCK pathway promotes leukocyte adhesion to
the microvasculature by aﬀecting the expression and func-
tion of adhesion molecules, including ICAM-1 [28, 29]
and integrins [30]. Moreover, ROCK causes ﬁrm adhesion
through the activation of ezrin, radixin, and moesin in
endothelialcells,whichjointlyformtheanchoringstructures
for leukocytes’ integrins [31, 32]. These ﬁndings suggest
that elevated activity of the Rho/ROCK pathway is involved
in the pathogenesis of diabetic microvasculopathy mediated
through leukocyte adhesion.
Rho/ROCK signaling is also involved in the pathogenesis
of VEGF-induced angiogenesis. In endothelial cells ROCK
pathway plays a critical role in VEGF-induced endothelial
migration by regulating stress ﬁber formation associated
withMLCphosphorylation[17,33].Moreover,recentinvivo
studieshavealsodemonstratedthattheROCKpathwayplays
a critical role in angiogenesis [34, 35].Journal of Ophthalmology 5
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Figure 3: Contractile impacts of ROCK activation in rat retinal vasculature. Intravitreal injections oﬂlysophosphatidic acid (LPA), Rho
activator, were performed into rat’s eyes over a period of 1 minute with a 33-gauge needle. The ﬁnal intraocular concentration of LPA was
20μM. We monitored the retinal ﬂuorescein with a scanning laser ophthalmoscope ((a) no injection, (b) 5 minutes after injection, (c) 10
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Figure 4: Rho/ROCK pathway and its activation in the development of diabetic retinopathy. RhoA is a small GTP-binding protein, and
Rho-kinase (ROCK) is its target protein. Glucose, TNF-α,a n dT G F - β, elevated in diabetic serum or vitreous, activate Rho/ROCK pathway
in endothelial cells or hyalocytes. ROCK activation induces endothelial damage mediated through inactivation of endothelial nitric oxide
synthase (eNOS), which has endothelial protective potential. Moreover, ROCK causes ﬁrm leukocyte adhesion through the increase of
ICAM-1expressionandactivationofezrin,radixin,andmoesin(ERM)inendothelialcells.ROCKalsohasimportantrolessuchasleukocyte
adhesion, endothelial migration, and contraction of proliferative membrane mediated through myosin light chain (MLC) phosphorylation
in diabetic retinopathy. These ﬁndings suggest that elevated activity of the Rho/ROCK pathway is involved in the pathogenesis of diabetic
microvascular damage, proliferative vitreoretinopathy, and retinal neovascularization.6 Journal of Ophthalmology
Previously we showed TGF-β2 contributes to transdiﬀer-
entiation of hyalocytes into α-SMA positive myoﬁbroblast-
like cells that causes hyalocyte-containing collagen gel con-
traction [19]. Moreover, we revealed that TGF-β2, overex-
pressed in the vitreous and contractile membranes of PDR
patients,activatesROCKpathwayandformsstressﬁbersand
contractions mediated through ROCK activation [20, 23].
These results suggest the central role of ROCK in the cicatri-




cular Damage. Fasudil, a potent and selective ROCK
inhibitor, is relatively safe and eﬀective in the treatment
of cardiovascular disease including cerebral and coronary
vasospasm, angina, hypertension, and heart failure with no
serious adverse side eﬀect in fasudil-treated patients [36].
In our animal experiments, intravitreal injection of fasudil
did not cause apparent electrophysiological or morpholog-
ical changes in retinal tissues at least within its eﬀective
concentrations [23]. However, several adverse eﬀects such
as hepatic function abnormal, intracranial hemorrhage, and
hypotension have been reported [37, 38]. We thus need
further examination regarding the safety and adverse eﬀects
of ROCK inhibitor before its clinical use in the ﬁeld of
intraocular diseases.
Nevertheless, we recently could reveal the therapeutic
potential of fasudil in the management of earlier stages
of DR. Treatment with intravitreal injection of fasudil
signiﬁcantly decreased retinal leukocyte adhesion in dia-
betic rat mediated through reduction of ROCK activation.
Moreover, fasudil eﬀectively suppressed endothelial damage,
even when leukocytes ﬁrmly adhered to the endothelium
(Figures 1(f)–1(i)). This suggests that fasudil directly causes
endothelial protection in addition to its impact on leukocyte
adhesion. Rho/ROCK inactivates endothelial nitric oxide
synthase (eNOS) in human umbilical venous cells [39].
eNOS generates physiological levels of nitric oxide (NO),
a potent vasodilator [40] and antiapoptotic factor [41, 42].
Fasudil treatment almost completely reversed the decreased
eNOS activity in diabetic rat retinas. In addition, the
protective eﬀect of fasudil on microvascular endothelial cells
was signiﬁcantly blocked by NOS inhibition with L-NAME,
without apparent eﬀect on leukocyte adhesion in vitro.
These ﬁndings suggest that fasudil has a direct endothelial
protectivepotential throughinductionofphysiologicallevels
of NO, synthesized by eNOS.
3.2. Antiangiogenic Properties of ROCK Inhibitor. We
demonstrated that ROCK inhibitor could inhibit
VEGF-elicited bovine retinal capillary endothelial cell
(BREC) migration and proliferation in vitro and corneal
neovascularization in vivo. A ROCK inhibitor fasudil
had inhibitory eﬀect on BREC migration with a scratch-
wound assay. Moreover, fasudil could inhibit VEGF-
induced BRECs [3H]-thymidine incorporation and ERK1/2
phosphorylation, whose activity indicates the proliferative
activities of endothelial cells in angiogenic processes [15].
In vivo, fasudil strongly attenuated VEGF-induced corneal
neovascularization in a corneal pocket assay [43].
3.3. ROCK Inhibition Suppresses Critical Contraction of
Proliferative Membrane. We could also demonstrate the
therapeutic potential of ROCK inhibitor fasudil in the
management of later stages of DR. In hyalocyte-containing
collagen gels assay, fasudil almost completely abolished the
PDR vitreous-induced collagen gel contraction mediated
through the suppression of MLC phosphorylation (Figures
2(a) and 2(b)). In experimental PVR rabbit model, fasudil
also eﬀectively disrupted α-SMA organization and blocked
contraction of proliferative membrane (Figures 2(c)–2(i)).
Statins, inhibitors of the 3-hydroxy-3-methyl-glutaryl-
(HMG-) CoA reductase, are widely used to reduce
endogenous cholesterol synthesis and improve hypercholes-
terolemia [44]. By inhibiting HMG-CoA reductase, statins
also block ROCK activation mediated through the meval-
onate pathway [45].
We demonstrated that simvastatin almost completely
inhibited vitreous-induced contraction of the collagen gels
in exvivo and proliferative membrane in experimental PVR
model mediated through ROCK inhibition [46]. Our results
indicate that ROCK inhibition suppresses PVR progression
in later DR stages.
3.4. Other Beneﬁcial Eﬀects of Fasudil on
Retinal Tissue during Diabetes
3.4.1. Vasodilatory Property and Improvement of Hemody-
namics in the Retinal Vessels. Development of chronic retinal
ischemic state aggravates diabetic retinopathy. Rho/ROCK
activation plays an important role in the pathogenesis of
vasoconstriction, such as cerebral and coronary spasm [47]
or hypertension [48], by NO-dependent mechanisms. We
could show that intravitreal injection of lysophosphatidic
acid, a potential Rho activator, induced severe retinal vessel
constriction (Figures 3(a)–3(c)). Recent studies suggested
that ROCK inhibitor fasudil improved hemodynamic states
in human [49], and also dilated rat retinal vessels, and
increases blood ﬂow [48]. These results suggest that fasudil
has preventable beneﬁt on retinal ischemia during diabetes
through improvement of hemodynamics in the retinal
vessels.
3.4.2. Retinal Neuroprotective Eﬀect of Fasudil. Retinal
ischemia secondary to DR causes functional and irreversible
damage not only in retina vasculature but also in retinal
neuronal cells. Chronic loss of neuronal cells from the inner
retina by increasing the frequency of apoptosis reduces the
thickness of the nerve ﬁber layer in diabetic retina [50].
Impaired retinal electrophysiology and neurodegeneration
have been shown in diabetic patients [51, 52]. Recent studies
revealedthatRho/ROCKpathwayalsoseemstobeassociated
with the pathogenesis of this neuronal damage. Abnormal
activation of the Rho/ROCK pathway is important in theJournal of Ophthalmology 7
pathogenesis of several neurological diseases [53]. In rat
retina, Rho/ROCK pathway is also involved in N-methyl-D-
aspartat-induced neurotoxicity in the rat retina. [54]. These
studies suggest that ROCK inhibitor would protect against
neuronal damage by acting directly on neurons. In fact, the
ROCK inhibitor Y-27632 increases regeneration of retinal
ganglion cell in the rat optic nerve crush model [55]. More-
over, ROCK inhibition attenuates ischemia-induced retinal
neuronal cell death by inhibiting leukocytes extravasation
and release of proinﬂammatory cytokines such as TNF-α or
IL-6 in vitro/vivo [56, 57]. These data suggest that inhibition
of Rho/ROCK pathway leads to neuroprotective eﬀect and
promote retinal cell survival during diabetes.
4. Conclusion
Rho/ROCKpathwayisinvolvedthroughoutthepathogenesis
of DR, particularly in diabetic retinal microvasculopathy,
neovascularization, and tractional retinal detachment asso-
ciated with cicatricial contraction of preretinal proliferative
membranes (Figure 4). Since we must consider frequent
intravitreal injections as administration method due to a
short biological half-life time of the compound in the
vitreous cavity, we are considering intravitreal implantation
of a slowly releasing drug-delivery system. For preventable
beneﬁt on progressing retinal microvascular damage and
keeping good visual acuity, timing of intravitreal fasudil
implantation prefers when early clinical DR ﬁndings such
as microaneurysm begin to appear. In addition, pre- and
postoperative intravitreal implantations for active PDR
patients with proliferative membrane are also considered
to be eﬀective for prevention of PVR and tractional retinal
detachment. Whereas further basic and clinical studies to
reveal the eﬀectiveness and safety of ROCK inhibitor are
needed for clinical use in the ﬁeld of eye diseases, ROCK
inhibition might become a novel therapeutic strategy in the
total management of DR from its early to late stages.
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